Reason for request
The actual benefit of these medicines is substantial.
Clinical Added Value
|no clinical added value||
In the absence of a study versus an active comparator, EFFENTORA provides no improvement in actual benefit (IAB V) compared to rapid-acting morphine drugs indicated in the management of breakthrough pain in adult patients who take morphine drugs to treat chronic cancer pain.